Crystalline forms and salt forms of a kinase inhibitor
AssigneeExelixis, Inc.
InventorsKirsten PHIZACKERLEY, Yizheng CAO, Dominika PCION
Life of this patent
Estimating the term…
Abstract
The present invention relates to crystalline free base of the tyrosine kinase inhibitor, Compound 1. The invention also relates to crystalline salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
Claims29
A crystalline solid of Compound 1
- wherein the crystalline solid of Compound 1 is selected from Compound 1 Form R, Compound 1 Form S, Compound 1 Form T, Compound 1 Form U, Compound 1 Form V, Compound 1 Form W, Compound 1 Form X, Compound 1 Form Y, and mixtures thereof.
(canceled)
8-43. (canceled)
A crystalline salt of Compound 1 having the structure
- wherein the crystalline salt of Compound 1 is selected from Compound 1 Hemi-edisylate Form A, Compound 1 Heminapadisylate Form A, Compound 1 Napsylate Form A, Compound 1 Napsylate Form B, Compound 1 Napsylate Form C, and mixtures thereof.
(canceled)
52-65. (canceled)
A crystalline fumaric acid salt of Compound 1
- wherein the crystalline fumaric acid salt of Compound 1 is selected from Compound 1 Hemifumarate Form C, Compound 1 Hemifumarate Form D, Compound 1 Hemifumarate Form E, Compound 1 Hemifumarate Form F, and mixtures thereof.
(canceled)
77-81. (canceled)
Dependencies are inferred from the claim text.